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Review of survival analyses published in cancer journals
DG Altman, BL De Stavola*, SB Love and KA Stepniewska
Medical Statistics Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, UK.
Summary Survival analysis has found widespread applications in medicine in the last 10-15 years. However,
there has been no published review of the use and presentation of survival analyses. We have carried out a
systematic review of the research papers published between October and December 1991 in five clinical
oncology journals. A total of 132 papers were reviewed. We looked at several aspects of study design, data
handling, analysis and presentation of the results. We found that almost half of the papers did not give any
summary oflength of follow-up; that in 62% of papers at least one end point was not clearly defined; and that
both logrank and multivariate analyses were frequently reported at most only as P-values [63/84 (75%) and
22/47 (47%) respectively]. Furthermore, although many studies were small, uncertainty of the estimates was
rarely indicated [in 13/84 (15%) logrank and 16/47 (34%) multivariate results]. The procedure for categorisa-
tion of continuous variables in logrank analyses was explained in only 8/49 (16%) papers. The quality of
graphs was felt to be poor in 43/117 (37%) papers which included at least one survival curve. To address some
of the presentational inadequacies found in this review we include new suggested guidelines for the presenta-
tion of survival analyses in medical journals. These would complement the statistical guidelines recommended
by several clinical oncology journals.
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Survival analysis has found widespread applications in
medicine in the last 10-15 years (Andersen, 1991), partic-
ularly in clinical oncology, and its correct application and
presentation is critically relevant for much of the cancer
literature. Although the use of statistical methods in medicine
has been subjected to much scrutiny (see Altman, 1982,
1991), we believe that there has not been any published
review of the use of survival analysis methods in medical
journals. Hence, we have carried out a systematic review of
the appropriateness of the application and presentation of
survival analyses in clinical oncology journals. We have
focused on the size of the studies being published, the ade-
quacy of the description ofthe data analysed (with particular
interest given to the length and quality of follow-up and the
clarity of the end points of interest) and the choice and
quality of univariate, multivariate and graphical analyses. In
the light of disappointing findings, we discuss existing
guidelines and present some new guidelines aimed in partic-
ular at presentation.
Methods
We examined all papers published in British Journal of
Cancer, European Journal of Cancer, Journal of Clinical
Oncology and American Journal ofClinical Oncology between
October and December 1991 which included analyses of sur-
vival data. There were 132 papers which reported at least one
of the following: Kaplan-Meier or actuarial survival curves;
logrank or related tests; parametric or semiparametric sur-
vival analyses. Those papers with survival data which did not
present any of these analyses, and thus were not included,
were largely phase I or II clinical trials.
The 132 papers were reviewed using a standard form that
had been tested in a small pilot study of 20 papers which
were read by all four authors. When the form was finalised
each paper was read by two of the authors according to a
balanced randomisation scheme. Disagreements between
reviewers were resolved in paired discussions and by discus-
sion between all four reviewers on the rare occasions when it
was necessary.
The assessment form included separate sections relating to
distinct aspects ofeach paper. It also included the time taken
by each author to extract the information from the paper
onto the form as an indication of the clarity of each paper.
The form is available from the authors upon request; the
contents of the form are summarised below.
Sample size
The importance that can be attached to the results from a
survival analysis depends on the selection and number of
subjects included. Hence, for each paper we recorded the
number of subjects studied and the maximum and minimum
number of subjects analysed by survival methods. The
number of events (e.g. deaths), which determines the statis-
tical power of a survival study, was also recorded.
Follow-up
The interpretation of the results of a survival analysis
depends in great measure upon the time frame in which the
study was carried out and the completeness of follow-up of
the subjects being investigated. Three critical dates define the
start and end of patient accrual and the cut-off date for the
analysis (Shuster, 1991). We checked whether these dates
were reported and also whether a summary of the length of
follow-up (such as a median) was given. We also noted
whether the authors mentioned if any subjects were lost to
follow-up and, if so, whether there was a statement on how
these were treated in the analysis.
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Endpoints
Survival analysis is based on the time measured from a
relevant time origin to a particular event of interest, for
example from date of surgery to recurrence of disease. How-
ever, the event of interest may not be observed for some
patients because of end-of-study censoring, loss to follow-up
or competing events (such as deaths from other causes). In
these cases the patient's survival is said to be censored sinceReview of survival analysis in cancerjournals
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his/her actual survival time is known to be larger than the
observed one.
Problems arise when reading a paper if the end point of
interest is not clearly defined or losses to follow-up and
competing events are not specified. For example, analyses of
time to death may be based on either deaths from any cause
or only cancer-related deaths. Likewise, in the analysis of
relapse-free survival time, deaths without apparent relapse
may be either treated as events or censored. In addition, a
single study may include survival analyses of more than one
end point, and the time origins for these may differ.
Additional problems arise when analysing relapse-free sur-
vival time, partly because of the lack of standardised
definitions. Relapse-free survival, disease-free survival, remis-
sion duration and progression-free survival are the terms
most commonly used; however, they are rarely defined
precisely. The first three imply that only patients who res-
ponded to treatment were analysed (although this is not
always the case), while for the last all patients are generally
included in the analysis. Which group of patients is actually
analysed directly affects the values of the estimated survival
probabilities, and this has important implications for the
interpretation of the results.
In order to evaluate the quality of the reviewed papers, we
therefore recorded the number of end points studied in each
paper, whether their time origin was stated, whether censor-
ing events were clearly reported and when relapse-free sur-
vival analyses were carried out whether it was clear which
patients were included.
Explanatory variables
When the effects of prognostic factors are examined using
survival analysis the results may be affected by the number of
variables examined, their coding and the presence of missing
values. We therefore recorded the total number of variables
examined in univariate analyses and the maximum number of
variables examined in multivariate analyses, whether con-
tinuous variables were recoded, and how they were categ-
orised. We also noted if missing values were reported and
discussed.
For many survival analyses it is important that the
variables are measured at or before the time origin, otherwise
their observation depends on what happens to the patient
between the time origin and the measurement of the variable.
An example is response to treatment when the time origin is
diagnosis. Comparisons of the survival probabilities of res-
ponders and non-responders, where survival is measured
from diagnosis, are still seen in the literature despite many
published warnings against them (Anderson et al., 1985;
Simon and Wittes, 1985). We recorded whether such incor-
rect analyses were reported.
Continuous explanatory variables need to be categorised to
produce survival plots and perform some types of analyses.
We recorded whether variables were reduced to two or more
categories and whether the choice of cut-off points was
explained. We recorded whether cut-off points were derived
from the data by minimising the associated P-value. This
so-called 'optimal' cut-off point approach is seriously flawed,
leading to overestimates of prognostic importance and P-
values that are far too small (Altman et al., 1994).
Graphicalpresentation
An accurate description of a data set in terms of survival is
provided by Kaplan-Meier or life table estimates, which are
usually presented in the form of a graph. We recorded the
type of survival curve and number of survival plots present-
ed. We also considered the quality of graphs; how points in
the graph were joined (steps are appropriate); whether there
were any marks indicating censoring times and if so whether
they were identified; whether the number of subjects at risk
or confidence intervals were given at any time; and whether
the numerical axes were reasonable. When survival curves
were presented for more than one group of patients, we
noted if different line types were used and if each line was
labelled.
Univariate analyses
We defined survival analysis as univariate where length of
survival was examined in relation to only one explanatory
variable at a time, hence ignoring the simultaneous effects of
other variables. The most common univariate analysis of
survival data compares the survival in two or more groups;
these could be treatment groups in clinical trials or risk
groups in observational studies. The most familiar method is
the logrank test, which also goes under several other names
including Mantel, Mantel-Haenszel, generalised Savage and
Mantel-Cox. There are also a class of tests (referred to here
as weighted logrank) which allow events occurring at
different times to have differing weights in the computation
(Harrington and Fleming, 1982), the best-known names
being the generalised Wilcoxon and the Gehan.
We therefore recorded which tests were used and, where
applicable, whether the use of unequal weights was expl-
ained. When the variable examined had three or more
ordered categories we also checked whether the more appro-
priate logrank test for trend (which seeks monotonic relation-
ship instead of just heterogeneity) was used.
We noted which papers used a Cox proportional hazards
regression model (Cox, 1972) with a single explanatory
variable in place of or in addition to the logrank test.
We recorded the type of information that was presented
about each analysis, including P-values, median survival
times or survival probabilities (e.g. for surviving 2 years) for
each group being compared, hazard ratio (within survival
analysis also known as relative risk) estimates and confidence
intervals.
The reporting of crude rates of observed events (calculated
ignoring the differing lengths of follow-up) was recorded.
Such simple indicators are easily misinterpreted.
Multivariate analyses
We defined a survival analysis as multivariate where survival
was examined in relation to at least two explanatory
variables simultaneously. We recorded if such an analysis
involved Cox regression analysis with baseline covariates
(time-fixed), Cox regression analysis with covariates meas-
ured over time (time-dependent), the fitting of a Weibull
model, multivariate logistic regression, adjusted Kaplan-
Meier or stratified logrank analyses. In addition, we noted
how the variables included in the full model were selected.
We noted whether the authors discussed the model-building
strategy (e.g. using stepwise analysis), the model assumptions
and the goodness of fit of the final model. We also recorded
the type of information presented to summarise the results,
including estimated regression coefficients, hazard ratios, P-
values and the computation of prognostic indices.
Subset analyses
We defined a subset analysis as one which did not use the full
number of subjects who could be used. We were interested in
whether any subset analyses were performed and, if so,
whether they were the main purpose of the paper. We
examined in particular how the analyses of complementary
subsets (e.g. patients with different stages of the disease) were
performed. The reporting of separate analyses on each subset
may lead to erroneous conclusions; tests for interaction are
more appropriate (Simon, 1982; Simon and Altman, 1994).
However, tests for interaction not recommended in small
samples owing to low power.
Abstracts
The abstract has many functions, the most important for this
study being the correct summary of results and conclusions.
We recorded whether a summary of follow-up was men-Reviewof survival analys in cancerjournals
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tioned and whether and how univariate and multivariate
analyses were reported. None of the journals in the study
used structured abstracts (Haynes et al., 1990) at the time of
the review.
Miscellanea
The majority of survival analyses are performed with the
help of computer programs. We noted if any information
was given in the papers about the commercial software used
to analyse the data.
As an overall appraisal of each paper we made subjective
assessments of the quality (recorded as adequate or not) of
the analyses, the description of the statistical methods and
the style of the graphical presentation. Since these assess-
ments were subjective, 'not adequate' was noted if either
reviewer recorded this option.
Further, to evaluate whether known statistical involvement
improved the quality of a paper, we noted if any author was
a member of a department of statistics or epidemiology.
Finally, we recorded any peculiarities which we noticed in
the papers and which were not covered by questions in the
form. They are reported in the relevant sections.
Results
The 132 papers in the study included 11 from the British
Journal of Cancer, 52 from Cancer, 20 from the European
Journal of Cancer, 32 from the Journal of Clinical Oncology
and 17 from the American Journal ofClinical Oncology. They
represent, respectively, 11%, 27%, 20%, 60%, 59% of all
papers published in the journal between October and
December 1991. Papers from all journals were considered
together; it was not our intention to compare journals.
Most of the papers described clinical trials (51%) or ret-
rospective observational studies (45%). Of the former, only
18 papers were about controlled clinical trials, and of the
latter only eight were treatment related. The remaining six
papers included a case-control study, the data from a pro-
spective screening study, three papers each describing anal-
ysis on selections of patients from several randomised clinical
trials and one paper which gave no information on sample
recruitment.
Reading the papers and completion of the form took a
median of 30 min per reader (range 12-80 min).
Sample size
The number of subjects in each analysis was not always clear.
A total of 123 papers out of 132 stated the number of
patients included in the study and the numbers examined in
survival analyses. In 21 out of 123 (17%) papers some study
patients were excluded from all survival analyses. Seventeen
included in their survival analyses a maximum of fewer than
30 patients and three papers a maximum of fewer than 15.
Many studies (78/126 with clear information, 62%) incl-
uded one or more additional survival analyses on a selection
of the subjects already analysed. Most of these papers (47/78)
included subsidiary analyses of less than half of the patients
included in the main survival analysis. Moreover, about a
third of these papers (29/78) included analyses of fewer than
30 subjects, and six fewer than 15 subjects.
Fewer than half (45%) of the papers gave the number of
events for each end point, with only two-thirds giving the
number of events for at least one of the end points analysed
within the paper.
Follow-up
Fewer than a quarter of papers reported all three dates of
start and end of accrual and cut-off point for the analysis
(Table I). The majority of the papers gave only the accrual
period, and nearly half of these (37/77) did not include any
summary of follow-up time. Several of the papers which did
not report any dates also did not summarise follow-up (9/16;
see first row in Table I).
Almost half of the papers did not give any summary of
follow-up. In at least two cases the event of interest had been
recorded for all patients by the time of the analysis, making a
summary of follow-up unnecessary. For those which did give
a summary, the median follow-up time was the most frequent
value presented, although the method used to compute it was
rarely specified (16/52, 31%). The other summaries reported
in these papers were the mean follow-up time, which is
inappropriate in most cases because of the likely skewness of
the observed survival times, and the range of follow-up times
(or only the minimum), which only reports the most extreme
cases and therefore is not very informative.
Losses to follow-up were mentioned in 34 papers, of which
12 declared no losses and the remaining 22 reported that
losses had occurred. However, 12 out of these 22 did not
state how losses were treated in the analyses.
Endpoints
The identification of end points was one of the hardest
aspects of the assessment of papers. In many papers one or
more end points was not clearly defined. Many papers refer-
red to 'overall survival'. We took this to imply that the end
point was death from any cause, but it would be unsafe to
assume that such usage was the rule, as in at least one paper
the term overall survival related to cancer deaths only.
With the exception of one paper, between one and six end
points were examined in univariate analyses (median 1) and
between one and seven end points (median 1) in multivariate
analyses. The one other paper examined univariate analyses
only, considering 40 end points. Only 65% (30/46) of papers
which also carried out a multivariate analysis examined the
same end points in the univariate and multivariate analyses.
Most of the remaining 16 papers considered in the mul-
tivariate analysis only a selection of the end points used in
the univariate analysis. The most common end point was
Table I Study dates and follow-up summary information
Dates given
Start End End Number (%) Summary offollow-up
ofaccrual ofaccrual offollow-up ofpapers Median Other None
No No No 16 (12) 5 2 9
Yes No No 3 (2) 2 1 0
No Yes No 0 (-) 0 0 0
No No Yes 3 (2) 1 1 1
Yes Yes No 77 (58) 28 12 37
Yes No Yes 2 (2) 0 1 1
No Yes Yes 0 (-) 0 0 0
Yes Yes Yes 31 (23) 16 3 12
All 132 (100) 52 20 60Review of survival analysis in cancer journals
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death, which was used in 106 (80%) papers, with explicitly
cancer death being used in 21 (16%) and eight papers using
both. Remission duration (progression-free survival) analysis
was carried out in 64 (48%) papers; it was often unclear
which patients were included. In five papers time to disease
progression was examined in two ways: firstly, death from
any cause was treated as an event and then the analysis was
rerun censoring survival times of subjects who died without
progressing.
In 62% of all papers, at least one end point was not clearly
defined. For example, among the 106 papers with death as an
end point, only 50 explicitly described the end point as either
any death or only cancer death. Likewise, treatment of
deaths was unclear in 39 out of 64 (61%) papers which
studied time to disease progression. In 48% of all papers the
time origin was not stated for at least one end point.
Explanatory variables
Across all the 113 papers using univariate analysis, the
median number of prognostic factors investigated was three
(range 1-28) with the number unclear in one paper. For the
47 papers using multivariate analysis, the median investigated
in the multivariate analysis was six (range 2-15) with the
number unclear in 14 papers. Table II shows the number of
patients used in survival analyses in relation to the number of
variables investigated by univariate and multivariate met-
hods.
In 28 papers the number of missing values was not given
for at least one of the prognostic factors tested, and in 34 out
of 63 (54%) papers with missing values there was no discus-
sion of the missing data in the text.
For logrank analysis, continuous variables have to be
categorised. Among 49 papers using categorised continuous
variables in logrank analysis, 76% dichotomised at least one
variable, with only eight giving a reason for the cut-off point
used. In Cox regression, continuous variables do not need to
be categorised, but of the 38 papers using this model with
continuous variables, 63% categorised at least one con-
tinuous variable; 75% of these papers gave no clear explana-
tion for the cut-off points used. In eight papers, no inform-
ation was provided about how any of the continuous
variables were used in the Cox analysis. Five out of 50
papers used the so-called optimal cut-off point method in the
logrank test or Cox regression analysis.
Some papers used variables which were not known at the
time origin. Fifteen of them compared the survival of res-
ponders and non-responders. At least three further papers
used other variables which were measured after the time
origin.
Graphicalpresentation
A survival curve was calculated in 95% of all papers. The
majority of these used the Kaplan-Meier method, other
methods being life table, actuarial and Nelson estimates (Nel-
son, 1969). However, almost a fifth did not name the method
of estimation used. At least one plot of a survival curve
(median 2, range 1-26) was presented in 117 papers. In 17%
of these papers at least one graph used slopes to connect
points of the survival curve. Censored observations were
rarely marked (29%). Few papers gave numbers of patients
at risk at given times (8%) or showed confidence intervals or
standard errors (7%).
Poor numerical axis scales were used, in at least one graph,
in 31 out of 117 papers (26%). The most common deficiency
was an unhelpful time scale - for example using intervals of
10 or 20 months or even 2000 days. In one paper percentage
survival of 120% was marked. In two further papers the
logarithmic transformation of survival scale was used without
any comments in the text.
There were 98 papers which included graphs comparing
survival in two or more groups. Fifteen of them did not use
different symbols or line types to distinguish the curves. In 51
papers curves were clearly labelled either directly or using a
special key. A further 41 papers described the curves in a
legend, while six papers used a mixture of these three
methods. Of 84 papers presenting more than one graph, 20%
were inconsistent with respect to at least one feature. Use of
differing line types and labelling of curves was not merely
attributable to the policy of the publishing journal.
We also noticed many errors caused mostly by authors'
carelessness, nevertheless making the understanding of papers
much more difficult. We were not explicitly looking for this
type of error so numbers quoted here underestimate the true
proportion of such papers. We found that in 9 out of 117
(8%) papers the graphs did not tally with the data: either
estimates of survival quoted in the text were different from
those presented in the graph (six papers) or graphs were
plotted beyond the stated maximum follow-up time (four
papers). In a further three papers, titles were swapped
between graphs, and in one paper the curves were incorrectly
labelled. In two other papers the graphs suggested that the
technique of estimation was different from the one specified
in the methods section.
Univariate analyses
Overall, 113 (86%) papers included at least one univariate
analysis. Of the remaining 19 papers, one reported mul-
tivariate analysis only and the other 18 were uncontrolled
clinical trials which were included in our review because they
presented graphs of survival.
Table III shows the methods of analysis used in the 113
papers. The majority used some form of logrank test; in 13
papers the test used was not stated. A weighted version of
the logrank test was used in 22 papers, always without any
explanation. The logrank test for trend was used in only one
of the papers, although ordered variables were used in at
least 36 further papers. Table IV summarises the information
Table II Number of variables examined in relation to the number of patients in the
study
Number ofvariables
Number ofpatients 1 2-5 6-10 11 + Unclear Total
Univariate analysisa
< 50 12 7 3 1 1 23
51-100 12 16 2 5 0 35
101-200 7 6 4 4 0 21
>201 9 8 9 6 0 32
All 40 37 18 16 1 112
Multivariate analysis
<50 - 4 0 0 0 4
51-100 - 4 2 0 5 11
101-200 - 1 6 2 2 11
> 201 - 7 5 2 7 21
All - 16 13 4 14 47
aOne paper was excluded because of unclear number of patientsReview of survival analysis in cancerjournals
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presented in connection with logrank tests; the majority gave
only P-values, and it was rare for estimates of survival
probabilities, survival rates at fixed time points or hazard
ratios to be given as well as P-values.
Eleven papers presented results of univariate Cox regres-
sion analyses, seven in addition to the logrank. Five papers
reported the estimated Cox coefficients or hazard ratios for
at least one of the univariate models, with an associated
measure of precision in four of them.
Confidence intervals are especially appropriate when pres-
enting the results ofcontrolled clinical trials. Only 4 of the 18
controlled trials in our study (22%) provided confidence
intervals for the treatment effect.
The crude rate of observed events was quoted in 38 (29%)
papers.
Multivariate analyses
Of the 113 papers which presented the results of univariate
analyses, 46 also included multivariate results. One additional
paper reported only a multivariate Cox regression analysis.
Multivariate analyses other than Cox regression were pres-
ented in only three papers: two were stratified logrank
analyses (both also presented the results of a Cox regression)
and one was a logistic regression model. In three papers it
was not clear what type of multivariate analysis had been
done.
Three papers reported variations of the Cox model.
Stratified Cox regression models were used in two papers and
a time-dependent Cox model was compared with the stan-
dard time-fixed specification in one study. The assumptions
underlying the Cox model were investigated in two papers
out of 43 (5%), one by plots of the logarithm of the
cumulative hazard and one by comparisons of the Cox
regression estimates with those from fully parametric models
(though the Cox model was presented). None of the papers
assessed goodness offit, but validation of the final model was
carried out in one paper using split-sample methods.
Few papers reported examining more than ten variables
(Table II). The choice of variables to examine was related to
the univariate analysis in 12 papers (being either all those
used or all those found to be significant in the univariate
analysis), but in 14 papers no explanation was given for the
set of variables used. In a further 13 papers it was unclear
which variables had been examined in the multivariate
analysis. The strategy for building the multivariate model
was unclear in 25 papers out of 47 (53%); over half of the
remaining papers (13) used a stepwise procedure.
Table III Type of univariate analysis (n = 113)
Number (%)
Type ofanalysis ofpapers
Median/n year % survival 5 (4)
Log-rank (equal weights) 62 (55)
Weighted log-rank 22 (19)
Cox regression 4 (4)
Other named testa 7 (6)
Unnamed test 13 (12)
aChi squared, Mann-Whitney, t-test, Kaplan-Meier.
Table IV Presentation of log-rank results (n = 84)
Presented results Number (%)
Estimate SE/CI P-value ofpapers
No No Noa 6 (7)
Yes No No 1 (1)
No Yes No 1 (1)
No No Yes 57 (68)
Yes Yes No 1 (1)
Yes No Yes 7 (8)
No Yes Yes 9 (11)
Yes Yes Yes 2 (2)
aAll papers stated whether variables were 'significant'.
Table V shows how the results of the multivariate analyses
were presented. Half of the papers gave at least the model
estimates, but six papers gave no results despite mentioning
that a multivariate survival analysis had been performed. A
prognostic index was computed in only two papers, and plots
of survival probability based on the multivariate model were
presented in six papers.
Subset analyses
Subset analyses were carried out in 52% of all papers, being
the main purpose of the study in almost a fifth and with a
reason given for at least some of the subset analysis in 43%
of these papers. Independent analysis of complementary
subsets was carried out in 39% of papers; no paper reported
a test of interaction.
Abstracts
Out of 72 papers which gave a summary of length of follow-
up in the body of the paper, 30 gave at least some of this
information in the abstract and one further paper gave a
different summary in the abstract and in the body of the
paper. The situation was better for a summary of survival,
with 42 out of the 63 who gave a summary in the body of the
paper also giving at least one summary in the abstract.
However, 11 papers that gave no summary of survival in the
body of the paper reported a median survival or n year
percentage in the abstract.
Of the 46 papers which contained both univariate and
multivariate analysis, nine gave no multivariate results in the
abstract and a further nine gave more emphasis to univariate
than to multivariate results.
Miscellanea
Only 19% of all papers mentioned use of any statistical
software, most of these using BMDP (17) and SAS (6).
Software was mentioned much more often when multivariate
analysis was performed, in 38% papers compared with 8%
papers without multivariate analysis.
Our subjective assessment of the papers indicated poor
quality of both analysis and presentation in most papers.
Only in 57 papers (43%) were univariate analyses felt to be
adequate and satisfactorily presented. For 22/67 papers
which presented only univariate results, we judged that mul-
tivariate analyses should have been performed. For mul-
tivariate analyses we felt that 17/47 papers performed an
adequate analysis and presented results satisfactorily. All
plots were felt to be acceptable in 63% papers which present-
ed survival graphs. The description of the statistical methods
was judged to be adequate in 64% of all papers, but the
content and presentation of the analyses were far less satis-
factory. In only 21% of all papers were presentation of
univariate and multivariate analyses and graphs considered
adequate.
The inclusion of a member of a department of statistics or
epidemiology as an author of the paper was not related to
the quality of the analyses, although it did seem to have
some positive effect on the description of the statistical
methods and the quality of the graphs included in the papers
(Table VI).
Table V Presentation of multivariate results (n = 47)
Presented results Number (%)
Estimate SE/CI P-value ofpapers
No No Noa 7 (15)
No No Yes 15 (32)
Yes Yes No 4 ( 9)
Yes No Yes 9 (19)
Yes Yes Yes 12 (26)
aHowever, one paper stated whether variables were 'significant' or
not.
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Table VI Subjective assessment of the quality of presentation and
statistician's involvement
Percentage ofpapers with
statistician among authors
No Unclear Yes Total (%)
Adequate (n = 70) (n = 31) (n = 31) (n = 132)
Description 61 58 77 64
Graphs 51 58 81 60
Univariate analysis 40 52 42 43
Multivariate analysis 66 52 55 58
Discussion
Many reviews of the use of statistics in medical journals have
found that the standard of the statistical component of pub-
lished papers is poor (see Altman 1982, 1991, for references).
Most reviews have been either of a particular type of study
(especially clinical trials) or were general examinations of all
statistical analyses in certain journals. A few authors have
concentrated on the use of specific statistical techniques, but
we are not aware of any previous investigation of the use of
survival analyses in published papers. The use of survival
analysis has increased markedly in recent years (Altman,
1991; Andersen, 1991), and it plays a particularly crucial role
in clinical cancer research. The papers included in our review
constituted 28% of all papers published in five clinical cancer
journals in the 3 months of the study.
The results of our review show that in most areas
examined a high proportion of papers were deficient. The
reporting of follow-up was very poor, with only 23% of
papers giving all three relevant dates (Table I). As well as the
dates of the study, it can be helpful to provide the median
follow-up time. There are, however, several ways of cal-
culating the median, not all of which are sensible (Shuster,
1991). The median follow-up time of all patients is of ques-
tionable value because it is directly affected by the times of
the observed events. Many authors provide the median
follow-up time of the survivors only, but this value can be
quite unstable if the number of survivors is small. Two more
plausible measures are the time from the median patient
entry to the cut-off date of the study and the median time to
censoring derived from a 'reverse' Kaplan-Meier analysis in
which the outcomes 'dead' and 'censored' are exchanged
(Shuster, 1991). Most papers in our study which reported the
median follow-up time did not explain how the median was
calculated.
More seriously, the majority of papers (62%) gave an
unclear description of at least one of the study end points.
Specific difficulties included the failure to specify whether
non-cancer deaths were treated as events or censored and
failure to specify how deaths without relapse were treated in
analyses of disease-free survival time. This issue is discussed
by Peto et al. (1977) and Gelber and Goldhirsch (1992). The
widespread absence of adequate information about end
points is rather surprising. It is hard to see how readers can
adequately assess a study without this information.
The large majority of papers reported the use of the log-
rank test for univariate analyses, with 12% not specifying the
method used. The most notable weakness that we identified
was the almost complete failure to use the logrank test for
trend when survival was compared in three or more ordered
groups. Such failure may greatly reduce the statistical power
of the analysis (Peto et al., 1977) so real associations may be
missed. Only one paper used this method out of 37 which
analysed such data.
The logrank test does not give any information about the
actual survival experience of the patients in the study. The
P-value is not a measure of the difference in survival between
groups. Further, P-values alone do not indicate the direction
of observed differences. Thus it is desirable also to quantify
the survival for each group of interest, using the median
survival time or the percentage surviving a given number of
years. The comparative survival experience of two groups can
be usefully assessed by the hazard ratio (Peto et al., 1977;
Gelber and Goldhirsch, 1992). When estimates such as these
are given it is also desirable to supply confidence intervals
(Simon, 1986; Machin and Gardner, 1989). Few papers in
our sample gave such information - of the 84 papers repor-
ting the results of logrank tests, less than a sixth reported
estimates of survival or gave standard errors or confidence
intervals (Table IV). In controlled trials it is especially impor-
tant to provide a confidence interval for the treatment effect:
in our sample only 4 of the 18 reports of controlled trials did
so.
About a third of the papers reported the results of mul-
tivariate analyses, about half of which included estimates of
some sort and a third gave standard errors or confidence
intervals (Table V). Although estimates were provided more
often than for univariate analysis, only 16 of the 47 papers
provided an adequate summary. Further, it was often unclear
exactly how the multivariate analyses had been carried out.
The logrank test and Cox regression analysis make up the
vast majority of published survival analyses, with both
methods being used in many papers. The methods of analys-
ing survival data have been described in various medical
statistics textbooks (Collett, 1994; Dawson-Saunders and
Trapp, 1994) and a few helpful journal articles (Peto et al.,
1977; Tibshirani, 1982; Elashoff, 1983; Christensen, 1987). Of
the papers that reported both univariate and multivariate
analyses 18/46 (39%) chose to highlight the univariate results
in the abstract. In some of these studies the univariate results
of interest were significant while the multivariate results were
not. The selective reporting of results in abstracts has been
noted before in other areas of research (Pocock et al., 1987;
G0tzsche, 1989).
Continuous variables were frequently analysed by creating
categories, but the basis for the choice of categories was
often missing. Five papers reported using the 'optimal' cut-
off point approach, which is not recommended (Altman,
1992; Altman et al., 1994).
Many of the studies were quite small; over a third of
papers included analyses of fewer than 30 patients. When
such analyses compare two (or more) groups there is very
poor statistical power to detect any real differences, although
this weakness is disguised unless a confidence interval is
supplied. Over half of the papers included some analysis of a
subset of the patients, but the reason for performing these
analyses was given in less than half of them. It is disappoin-
ting that so many studies reported the results of separate
significance tests performed on complementary subgroups.
Here, too, confidence intervals are much more revealing than
P-values. It is also disappointing to see so many papers
(11%) comparing the survival of patients who do or do not
respond to treatment or comparisons of other groups defined
by events occurring after the start of follow-up, given the
numerous published admonishments against such analyses
(e.g. Anderson et al., 1985; Simon and Wittes, 1985). An
association between response and survival is generally to be
expected, and provides no information about treatment
efficacy.
Many of the deficiencies we have described can be
classified as poor reporting rather than errors in metho-
dology, but this should not be taken to suggest that the
identified weaknesses are unimportant. Omitted or ambi-
guous descriptions of the methods used makes it difficult or
impossible for readers to know what was done. Similar
observations were made by Hokanson et .al. (1986), who
surveyed the statistical methods used in several cancer jour-
nals. Authors should adhere to the advice of the Interna-
tional Committee of Medical Journal Editors (1991): 'Des-
cribe statistical methods with enough detail to enable a
knowledgeable reader with access to the original data to
verify the reported results'. Poor reporting is one of the
failings that is most amenable to improvement. We hope that
referees and editors will be more vigilant on this aspect in
future.
We also identified many presentational problems. In par-
ticular, there was a general tendency to present results as
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P-values without quantitative results, and an absence of
confidence intervals. Many of the survival plots were of poor
quality. Most of the problems were not too serious, but there
was considerable scope for improved presentation of inform-
ation in graphs (see Greenberg et al., 1983). However, the use
of sloping lines to join Kaplan-Meier survival curves gives
incorrect estimates (Peto et al., 1977). Some of the
deficiencies may have been due to limitations of the software
used.
We looked at the advice currently given by each of the
journals in our survey in their instructions to authors regar-
ding statistical aspects of submitted papers. The British Jour-
nal of Cancer and the European Journal of Cancer make no
mention of statistics. Cancer and the Journal of Clinical
Oncology recommend authors to consult the guidelines of
Simon and Wittes (1985). The latter also recommends the
guidelines of Zelen (1983). The American Journal of Clinical
Oncology refers to the 'NCI Methodologic Guidelines for
Reports ofClinical Trials' published in theirjournal. Eight of
the ten points in this unattributed document (Anonymous,
1986) are in fact taken from Simon and Wittes (1985). The
original recommendation about quality control of data was
omitted.
The most quoted guidelines (Simon and Wittes, 1985) are
cited in some form by three of the five journals in our study
(and also by the Journal of the National Cancer Institute).
Their nine points cover quality control of data; accounting
for patients and describing follow-up; rates of ineligibility or
missing data; the need for an intention to treat analysis in
randomised trials; sample size, power and confidence inter-
vals; planned sample size and reasons for stopping patient
accrual; dangers of using non-randomised controls in treat-
ment comparisons and the unacceptability of comparing sur-
vival of responders and non-responders; description of
patients, extrapolation and subset analyses; and finally a
statement of the principle of adequate description already
referred to above. Zelen (1983) made a similar set of recom-
mendations, and also discussed other issues including the
early reporting of clinical trials. These two sets of sensible
guidelines cover many of the issues that we investigated in
our review. It is clear that many authors have not taken
notice of these recommendations, and that referees and
editors have not insisted that authors do so.
These sets of guidelines do not, however, include much
advice on the presentation of the results of studies of sur-
vival. There seems to be little published advice elsewhere on
summarising the data and presenting the results of the
analyses, although some authors have considered some of the
relevant issues, mostly in the context of the reporting of
clinical trials (Greenberg et al., 1983; Meinert, 1986; Gelber
and Goldhirsch, 1993). Our findings suggest that guidelines
for presentation of survival analysis in medical journals
would be useful. Some suggested guidelines are shown in the
appendix. These largely follow from the most obvious repor-
ting deficiencies described above. The methodological stan-
dard of papers published in cancer journals could be imp-
roved if authors were made to adhere to these or similar
guidelines for presentation as well as the other guidelines
discussed above (Zelen, 1983; Simon and Wittes, 1985).
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Appendix:
Suggested guidelines for presentation ofsurvival analyses
Presentation ofdata
* Describe the recruitment and analysis dates.
* Describe the reason for the sample size.
* Report a summary of follow-up, such as the median and
quartiles computed by the reverse Kaplan-Meier method.
* Report how many subjects were lost to follow-up and
whether, and how, they had been included in the analyses.
* Report the number of events for each end point.
Presentation ofmethods
* Give a clear definition of each end point being considered,
i.e. define the time origin, the event of interest and the
circumstances where survival times are censored.
* Name the method used for estimating survival pro-
babilities.
* Name any test used in the analyses; in particular, justify
the use of weighted logrank tests.
* Report the test for trend when ordered categorical
variables are examined.
* When performing univariate or multivariate analyses,
report all the covariates examined, their frequency of miss-
ing values and the definition of the categories used (if any)
whether the covariate is significant or not.
* When Cox regression analyses are performed, describe the
criteria used to select the variables in the initial model, the
procedure to specify the final model and describe any
methods used to assess the model assumptions.
* Name the software used.
Presentation ofresults
* Give a summary of overall survival: preferably median
and/or percent surviving n years.
* If study is a randomised clinical trial, give separate sum-
maries of survival for each treatment group.
When reporting the results of any test, give the test statis-
tic, the degrees of freedom (when applicable) and the exact
P-value.
* When presenting results of a logrank test also report the
numbers of observed and expected events in each group
(desirable).
* When comparing survival in two or more groups, give an
estimate of the survival in each group, e.g. median sur-
vival time, survival probabilities for a particular time
point, hazard ratio.
* When presenting the results of a Cox regression analysis,
report the estimated coefficients (or estimated hazard
ratios), measures of their precision (i.e. standard errors or
confidence intervals) and/or the associated P-values.
* Do not use crude rates to summarise the data.
Graphs
* Use meaningful time intervals.
* Use a step function to join Kaplan-Meier survival
estimates.
* Mark the survival time of censored observations (desir-
able).
* If several curves are reported in the same plot use different
lines type (desirable).
* Give number of patients at risk at selected time points
(desirable).
* Mark confidence intervals or standard errors for some of
the selected time points (desirable).
Abstract
* Include in the abstract summaries offollow-up and survival
(separately by treatment group if applicable) and the final
results of both univariate and multivariate analyses (when
applicable).
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